12 Health Care Stocks Moving In Friday's After-Market Session

Benzinga · 03/06 21:05
Gainers
- Edesa Biotech (NASDAQ:EDSA) stock moved upwards by 17.3% to $7.65 during Friday's after-market session. The market value of their outstanding shares is at $30.1 million.
- Lunai Bioworks (NASDAQ:LNAI) stock rose 6.78% to $0.25. The company's market cap stands at $8.7 million.
- MindWalk Holdings (NASDAQ:HYFT) stock rose 4.5% to $1.16. The market value of their outstanding shares is at $54.6 million.
- Lexaria Bioscience (NASDAQ:LEXX) shares moved upwards by 3.76% to $0.86. The company's market cap stands at $19.2 million.
- Fractyl Health (NASDAQ:GUTS) shares rose 3.54% to $0.5. The market value of their outstanding shares is at $76.4 million.
- Citius Pharmaceuticals (NASDAQ:CTXR) shares moved upwards by 2.96% to $0.86. The market value of their outstanding shares is at $21.2 million.
Losers
- Harvard Bioscience (NASDAQ:HBIO) shares declined by 12.6% to $0.48 during Friday's after-market session. The market value of their outstanding shares is at $25.5 million.
- AN2 Therapeutics (NASDAQ:ANTX) shares decreased by 4.57% to $2.72. The company's market cap stands at $46.8 million.
- Solid Biosciences (NASDAQ:SLDB) stock declined by 2.67% to $6.57. The market value of their outstanding shares is at $436.8 million.
- SCYNEXIS (NASDAQ:SCYX) shares fell 2.51% to $0.78. The market value of their outstanding shares is at $33.2 million. As per the press release, Q4 earnings came out 2 days ago.
- Invivyd (NASDAQ:IVVD) shares decreased by 2.23% to $1.76. The company's market cap stands at $490.6 million. As per the press release, Q4 earnings came out yesterday.
- Lucid Diagnostics (NASDAQ:LUCD) stock fell 2.15% to $1.37. The company's market cap stands at $183.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.